Prof. Yechezkel Barenholz Ph.D.
Prof. Barenholz is a recognized expert in the field of drug delivery. Prof. Barenholz is the co-inventor of DoxilTM, a liposomal formulation of doxorubicin for cancer treatment marketed in the US by Johnson & Johnson and in Europe by Schering Plough (as Caelyx). Prof. Barenholz serves as head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry of the Hadassah Medical School at the Hebrew University of Jerusalem.
- Member of the Compensation and Nominating and Corporate Governance Committee
